DE | EN

Dr. med. Andrew Berdel

Current affiliations

Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)

Publications

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C (2023) In: Annals of Hematology, 102 Type of Publication: Research article (journal)
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Kessler T, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Schmidt H, Lenz G. Mesters R, Berdel WE (2020) In: (eds.), . (no publisher available). Type of Publication: Research article in edited proceedings (conference)
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020) In: Cancers, 12(6) Type of Publication: Research article (journal)